Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilovertamab + Paclitaxel in Metastatic Breast Cancer
NCT02776917Phase 1Completed
- Sponsor
- Barbara Parker
- Start
- Aug 2018
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cirmtuzumab in breast cancer, sponsored by Barbara Parker. Primary endpoint: Dose-limiting Toxicities at 4 weeks. Started Aug 2018; status: completed.
02
Drugs
cirmtuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02776917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02776917.